Overcoming challenges in GPCRs with a fully integrated high-throughput antibody discovery workflow

Poster Overview:

Transform your approach to GPCR antibody discovery with this detailed poster that demonstrates how Alloy Therapeutics’ PerformAb^TM yeast display platform and innovative technologies can overcome significant challenges in targeting these complex transmembrane proteins. Download the poster to discover:

Unprecedented repertoire coverage: 1 billion antibodies captured for nearly 100% repertoire coverage, compared to just 0.002% with traditional hybridoma methods.
Native conformation screening: Cell-based GPCR filtering ensures antibodies recognize therapeutically relevant conformations, allowing only the most viable candidates to advance through development.
Accelerated discovery with Al-powered selection: Entire workflow, from immunization to lead characterization, completed in as few as 3-4 months, using high-throughput, AI-ML in silico selection to identify diverse, developable therapeutic candidates.

Complete this form to download and view the poster

Name(Required)

Email(Required)

Organization(Required)

By clicking submit you consent to receive email communications about Alloy Therapeutics products and services and agree to our Terms. Your data will be processed in accordance with our Privacy Policy. You may opt out at any time.

Accelerating antibody discovery

Discover how Alloy Therapeutics' antibody discovery capabilities enable:

Access to the broadest possible diversity through ATX-Gx^TM human transgenic mice
Advanced enrichment and Al/ML-powered in silico repertoire mining to identify optimal therapeutic candidates
Comprehensive characterization including affinity, specificity, epitope binning, and developability assessment
Qualified therapeutic leads delivered in as few as 3-4 months with high-throughput end-to-end workflows and proven expertise
Work closely and collaboratively with leading drug discovery experts to navigate your challenging discovery campaign